h-89 and cicaprost

h-89 has been researched along with cicaprost* in 5 studies

Other Studies

5 other study(ies) available for h-89 and cicaprost

ArticleYear
Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins.
    Circulation research, 2005, Jan-07, Volume: 96, Issue:1

    There is concern that cyclooxygenase (COX)-2 inhibitors may promote atherothrombosis by inhibiting vascular formation of prostacyclin (PGI2) and an increased thrombotic risk of COX-2 inhibitors has been reported. It is widely accepted that the prothrombotic effects of COX-2 inhibitors can be explained by the removal of platelet-inhibitory PGI2. Using microarray chip technology, we have previously demonstrated that thrombomodulin (TM) mRNA is upregulated in cultured human coronary artery smooth muscle cells by the stable prostacyclin mimetic iloprost. This study is the first to demonstrate a stimulation of the expression of functionally active thrombomodulin in human smooth muscle cells by prostaglandins, endogenously formed via the COX-2 pathway. Because TM is an important inhibitor of blood coagulation, these findings provide a novel platelet-independent mechanism to explain the prothrombotic effects of COX-2 inhibitors. The full text of this article is available online at http://circres.ahajournals.org.

    Topics: Alprostadil; Blood Coagulation; Bucladesine; Carotid Artery Diseases; Carotid Artery, Internal; Cells, Cultured; Colforsin; Coronary Vessels; Culture Media, Serum-Free; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Epoprostenol; Etoricoxib; Gene Expression Profiling; Gene Expression Regulation; Humans; Iloprost; Isoquinolines; Mammary Arteries; Membrane Proteins; Models, Biological; Myocytes, Smooth Muscle; Oligonucleotide Array Sequence Analysis; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyridines; Receptors, Prostaglandin; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP3 Subtype; RNA, Messenger; Saphenous Vein; Second Messenger Systems; Sulfonamides; Sulfones; Tetradecanoylphorbol Acetate; Thrombomodulin; Thrombophilia; Vasodilator Agents

2005
Induction of hyaluronic acid synthase 2 (HAS2) in human vascular smooth muscle cells by vasodilatory prostaglandins.
    Circulation research, 2004, Mar-19, Volume: 94, Issue:5

    Hyaluronic acid (HA) is a prominent constituent of the extracellular matrix of atherosclerotic vascular lesions in humans known to modulate vascular smooth muscle phenotype. The regulation of HA synthesis by vasodilatory prostaglandins was analyzed in human arterial smooth muscle cells (SMCs). The prostacyclin analogue, iloprost (100 nmol/L), markedly increased pericellular formation of HA coats and HA secretion into the cell culture medium in human arterial SMCs (8.7+/-1.6-fold). Expression of HA synthase 2 (HAS2) was determined by semiquantitative RT-PCR and found to be strongly upregulated at concentrations of iloprost between 1 and 100 nmol/L after 3 hours. Furthermore, endogenous cyclooxygenase-2 (COX2) activity was required for basal expression of HAS2 mRNA in SMCs in vitro. Total HA secretion in response to iloprost was markedly decreased by RNA interference (RNAi), specific for HAS2. In addition, siRNA targeting HAS2 strongly increased the spreading of human SMCs compared with mock-transfected cells. HAS2 mRNA levels were also stimulated by a selective prostacyclin receptor (IP) agonist, cicaprost (10 nmol/L), prostaglandin E(2) (10 nmol/L), and the EP(2) receptor agonist, butaprost (1 micromol/L). Induction of HAS2 mRNA and HA synthesis by prostaglandins was mimicked by stable cAMP analogues and forskolin. In human atherectomy specimens from the internal carotid artery, HA deposits and COX2 expression colocalized frequently. In addition, strong EP(2) receptor expression was detected in SMCs in HA-rich areas. Therefore, upregulation of HAS2 expression via EP(2) and IP receptors might contribute to the accumulation of HA during human atherosclerosis, thereby mediating proatherosclerotic functions of COX2.

    Topics: 6-Ketoprostaglandin F1 alpha; Acetophenones; Alprostadil; Arteriosclerosis; Becaplermin; Benzopyrans; Bucladesine; Carotid Artery Diseases; Carotid Artery, Internal; Cells, Cultured; Colforsin; Cyclic AMP; Cyclooxygenase 2; Enzyme Induction; Epoprostenol; Extracellular Matrix; Glucuronosyltransferase; Humans; Hyaluronan Synthases; Hyaluronic Acid; Iloprost; Indoles; Isoenzymes; Isoquinolines; Macrophages; Maleimides; Membrane Proteins; Muscle Cells; Muscle, Smooth, Vascular; Pertussis Toxin; Platelet-Derived Growth Factor; Prostaglandin-Endoperoxide Synthases; Proto-Oncogene Proteins c-sis; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP2 Subtype; RNA, Messenger; RNA, Small Interfering; Sulfonamides; Vasodilator Agents

2004
Mechanism of cicaprost-induced desensitization in rat pulmonary artery smooth muscle cells involves a PKA-mediated inhibition of adenylyl cyclase.
    American journal of physiology. Lung cellular and molecular physiology, 2004, Volume: 287, Issue:2

    Long-term infusion of prostacyclin, or its analogs, is an effective treatment for severe pulmonary arterial hypertension. However, dose escalation is often required to maintain efficacy. The aim of this study was to investigate the mechanisms of prostacyclin receptor desensitization using the prostacyclin analog cicaprost in rat pulmonary artery smooth muscle cells (PASMCs). Desensitization of the cAMP response occurred in 63 nM cicaprost after a 6-h preincubation with agonist. This desensitization was reversed 12 h after agonist removal, and resensitization was inhibited by 10 microg/ml of cycloheximide. Desensitization was heterologous since desensitization to other G(s)alpha-adenylyl cyclase (AC)-coupled agonists, isoproterenol (1 microM), adrenomedullin (100 nM), or bradykinin (1 microM), was also reduced by preincubation with cicaprost. The reduced cAMP response to prolonged cicaprost exposure appeared to be due to inhibition of AC activity since the responses to the directly acting AC agonist forskolin (3 microM) and the selective AC5 activator NKH-477 were similarly reduced. Expression of AC2 and AC5/6 protein levels transiently decreased after 1 h of cicaprost exposure. The PKA inhibitor H-89 (1 microM) added 1 h before cicaprost preincubation (6 h, 63 nM) completely reversed cicaprost-induced desensitization, whereas the PKC inhibitor bisindolylmaleimide (100 nM) was only partly effective. Desensitization was not prevented by the G(i) inhibitor pertussis toxin. In conclusion, chronic treatment of PASMCs with cicaprost induced heterologous, reversible desensitization by inhibition of AC activity. Our data suggest that heterologous G(s)alpha desensitization by cicaprost is mediated predominantly by a PKA-inhibitable isoform of AC, most likely AC5/6.

    Topics: Adenylyl Cyclases; Animals; Antineoplastic Agents; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Down-Regulation; Epoprostenol; In Vitro Techniques; Isoquinolines; Muscle, Smooth, Vascular; Protein Kinase C; Pulmonary Artery; Rats; Sulfonamides; Vasodilator Agents

2004
The alpha, but not the beta, isoform of the human thromboxane A2 receptor is a target for prostacyclin-mediated desensitization.
    The Journal of biological chemistry, 2000, Jul-07, Volume: 275, Issue:27

    In this study, we examined the effects the prostacyclin receptor (IP) agonist cicaprost exhibited on U46619-mediated thromboxane A(2) receptor (TP) signaling in platelets and compared it to that which occurs in human embryonic kidney (HEK) 293 cells stably overexpressing the individual TPalpha or TPbeta isoforms. Consistent with previous studies, cicaprost abrogated U46619-mediated platelet aggregation and mobilization of intracellular calcium ([Ca(2+)](i)). In HEK 293 cells, signaling by TPalpha, but not TPbeta, was subject to IP-mediated desensitization in a protein kinase A-dependent, protein kinase C-independent manner. Desensitization of TPalpha signaling was independent of the nature of the IP agonist used, the level of IP expression, or the subtype of G(q) protein. Signaling by TP(Delta)(328), a truncated variant of TP devoid of the divergent residues of the TPs, or by TPalpha(S329A), a site-directed mutant of TPalpha, were insensitive to IP agonist activation. Whole cell phosphorylations established that TPalpha, but not TPbeta or TPalpha(S329A), is subject to IP-mediated phosphorylation and that TPalpha phosphorylation is inhibited by H-89. Thus, we conclude that TPalpha, but not TPbeta, is subject to cross-desensitization by IP mediated through direct protein kinase A phosphorylation at Ser(329) and propose that TPalpha may be the isoform physiologically relevant to TP:IP-mediated vascular hemostasis.

    Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Blood Platelets; Calcium; Cell Line; Cyclic AMP-Dependent Protein Kinases; Epoprostenol; Humans; Inositol Phosphates; Isoquinolines; Mutation; Phosphorylation; Platelet Aggregation; Protein Isoforms; Receptors, Epoprostenol; Receptors, Prostaglandin; Receptors, Thromboxane; Signal Transduction; Sulfonamides; Vasoconstrictor Agents

2000
The effect of prostacyclin mimetics on neutrophil function.
    Advances in experimental medicine and biology, 1997, Volume: 407

    Topics: Acetates; Animals; Cell Aggregation; Cyclic AMP; Epoprostenol; Iloprost; Imidazoles; Isoquinolines; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Oxazoles; Peritoneal Cavity; Phenoxyacetates; Pyrrolidinones; Rats; Rolipram; Second Messenger Systems; Sulfonamides

1997